By Billy Candra 
Metastatic cancer remains a formidable challenge in modern medicine, responsible for the vast majority of cancer-related deaths worldwide. While primary tumours are often treatable, the spread of cancer cells from their point of origin to distant organs, forming secondary tumours known as metastases, drastically reduces survival rates and complicates treatment. A groundbreaking new study published in the prestigious journal Nature Medicine offers a significant ray of hope, demonstrating that the well-established cardiac drug digoxin, administered at a low dosage, can effectively weaken these circulating tumour cell (CTC) clusters, thereby potentially reducing the risk of metastasis. This collaborative research, spearheaded by a team from ETH Zurich, the University Hospitals of Basel and Zurich, and the Basel-Land Cantonal Hospital, represents a promising step towards a novel strategy to combat one of cancer’s deadliest aspects.
The Devastating Impact of Metastasis: A Global Health Crisis
Cancer metastasis is not merely a complication; it is the primary cause of mortality for an estimated 90% of cancer patients. Globally, around seven million individuals succumb to metastatic disease each year, a staggering figure that underscores the urgent need for more effective preventative and therapeutic strategies. The process begins when primary tumours, such as those found in breast, prostate, or colorectal cancer, continuously shed cancer cells into the bloodstream. These individual cells, known as circulating tumour cells (CTCs), are incredibly resilient. They can travel through the circulatory system, often aggregating into small clusters of a handful to a dozen cells. These CTC clusters are far more dangerous than single CTCs; they possess a significantly enhanced metastatic potential, acting as fertile seeds that can successfully implant in distant organs, evade immune surveillance, and proliferate into new, often aggressive, metastatic tumours.
Breast cancer serves as a poignant example of this devastating progression. While early-stage breast cancer boasts high survival rates, the prognosis plummets dramatically once metastases are detected. Tens of thousands of women worldwide continue to die from metastatic breast cancer annually, despite advances in surgery, chemotherapy, radiation, targeted therapies, and immunotherapies. The insidious nature of metastatic disease lies in its ability to affect vital organs, leading to widespread organ dysfunction and treatment resistance. Existing treatments for metastatic cancer are often palliative, aiming to extend life and improve quality of life rather than offering a definitive cure. This grim reality has driven oncologists and researchers to tirelessly seek innovative ways to intercept the metastatic cascade, particularly by targeting the very mechanisms that enable cancer cells to spread and thrive.
Unveiling the Achilles’ Heel of CTC Clusters
The research team’s journey to this discovery began with a meticulous screening process, highlighting a methodical approach to scientific inquiry. In 2019, researchers at ETH Zurich embarked on an extensive high-throughput screening campaign. They systematically tested over 2,400 different substances in cell cultures, meticulously searching for compounds that could specifically target and disrupt clusters of circulating tumour cells. This rigorous investigative phase identified digoxin as a potent candidate.
Digoxin, an active ingredient derived from the foxglove plant (Digitalis sp.), is not new to medicine. It has been a cornerstone in the treatment of various heart conditions, including heart failure and atrial fibrillation, for decades. Its long-standing clinical use means that its pharmacokinetic profile, safety parameters, and potential side effects at therapeutic dosages are well-understood. This pre-existing knowledge of digoxin’s safety and tolerability in humans offered a significant advantage, potentially accelerating its repurposing for oncology.
The mechanism by which digoxin weakens CTC clusters is elegant and precise. The "Achilles’ heel" of these clusters, as identified by the researchers, lies in the sodium-potassium pumps (Na+/K+-ATPases). These vital ion pumps are embedded within the membranes of all cells, including tumour cells, and are responsible for maintaining cellular homeostasis by actively transporting sodium ions out of the cell and potassium ions into the cell. Digoxin, a known inhibitor of these pumps, works by binding to them and thereby suppressing this crucial ion exchange. When the sodium-potassium pumps are blocked, the cells’ internal ion balance is disrupted. Specifically, this leads to an increased intracellular sodium concentration, which in turn triggers a cascade of events, including an influx of calcium ions from the outside of the cell membrane. This surge in intracellular calcium weakens the intercellular junctions and adhesion molecules that bind the cancer cells together within a cluster, causing the clusters to effectively fall apart. The disintegration of these cohesive units significantly impairs their ability to survive in the bloodstream, evade immune detection, and successfully initiate new tumours in distant organs.
A Promising Clinical Pilot Study: Evidence in Patients
Following promising pre-clinical findings, the researchers moved swiftly to a pilot clinical study, the results of which are now published in Nature Medicine. This study involved nine patients diagnosed with metastatic breast cancer, a patient population desperately in need of new therapeutic avenues. The patients were administered digoxin at a low and safe dosage for a period of one week. The choice of a low, clinically established dosage was critical, ensuring patient safety while evaluating the drug’s efficacy against CTC clusters.
The results of this small yet impactful clinical trial were highly encouraging. The administration of digoxin led to a statistically significant decrease in the number of cells per cluster, with an average reduction of 2.2 cells. While this number might seem modest in isolation, its significance becomes profound when considering the typical size of these clusters, which are often composed of only a handful of cells. For instance, if a cluster typically consists of 5-7 cells, a reduction of 2.2 cells represents a substantial weakening and destabilization of the cluster’s integrity. As Nicola Aceto, Professor of Molecular Oncology at ETH Zurich and the study’s principal investigator, succinctly explains, "Breast cancer metastasis depends on CTC clusters. The larger they are, the more successful they are." By reducing the size and cohesion of these clusters, digoxin effectively disarms them, making them less capable of successfully forming new metastases. This finding offers compelling clinical evidence for the potential of this novel approach in vivo.
The Broader Implications and Future Trajectory
While the study presents a compelling case for digoxin’s role in preventing metastasis, it also highlights an important nuance: digoxin alone does not eliminate existing tumours. Its primary action, as demonstrated, is to weaken the adhesive forces within CTC clusters, thereby impeding their metastatic potential. Consequently, the drug would likely need to be administered in combination with other established cancer therapies designed to kill existing cancer cells, such as chemotherapy, targeted agents, or immunotherapies. This synergistic approach could potentially offer a more comprehensive treatment strategy, targeting both the primary tumour and the metastatic spread.
The research team is not resting on its laurels. A key next step involves optimising the active ingredient itself. The ETH spin-off, Page Therapeutics, has already been established with the specific mission of developing novel molecules based on the digoxin scaffold. These new compounds aim to enhance the efficacy of dissolving CTC clusters while potentially refining the safety profile or improving pharmacokinetic properties. This translational effort underscores the commitment to bringing this scientific discovery closer to widespread clinical application.
Furthermore, Professor Aceto and his team are already expanding their research horizons. Recognizing that the fundamental mechanism of CTC cluster formation and spread is common across many cancer types, initial experiments are underway to investigate digoxin’s potential effectiveness in other highly metastatic cancers, including prostate cancer, colorectal cancer, pancreatic cancer, and melanoma. If successful, this could broaden the impact of their findings significantly, offering hope to a much wider patient population.
A Paradigm Shift in Metastasis Prevention
This study exemplifies the power of collaborative, multidisciplinary research. The seamless cooperation between ETH Zurich, with its cutting-edge research capabilities, and the University Hospitals of Basel and Zurich, along with the Basel-Land Cantonal Hospital, which provided the crucial clinical infrastructure for patient recruitment and trial execution, was instrumental to the study’s success. Such partnerships are vital for translating basic scientific discoveries into tangible clinical benefits for patients.
The repurposing of an existing drug like digoxin offers several distinct advantages. Firstly, it bypasses the lengthy and costly early-stage drug development process, which can take over a decade and billions of dollars for novel compounds. Given that digoxin’s safety and pharmacology are well-understood, clinical trials can proceed more rapidly to later stages, accelerating its potential availability to patients. Secondly, it could make an effective metastasis-preventing therapy more affordable and accessible globally, an important consideration in resource-constrained healthcare systems.
Looking ahead, the development of therapies that specifically target CTC clusters represents a potential paradigm shift in cancer treatment. Instead of solely focusing on eliminating established metastases, this approach aims to prevent their formation in the first place, thereby potentially transforming the prognosis for patients with high-risk primary tumours. While larger, more extensive clinical trials will be necessary to confirm these initial findings, establish optimal dosing regimens, evaluate long-term efficacy, and assess potential side effects in broader patient populations, the initial results offer a compelling vision for a future where metastatic disease is no longer an inevitable death sentence, but a manageable and preventable aspect of cancer care. This research provides a robust foundation for an innovative strategy that could fundamentally alter the trajectory of cancer patient survival.
